Npj Breast Cancer
Overview
Npj Breast Cancer is a scientific journal, published since 2015 in English. The journal's country of origin is United States.
Details
Details
Abbr.
NPJ Breast Cancer
Start
2015
End
Continuing
e-ISSN
2374-4677
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 7869
46
SJR / Ranks: 956
2275
CiteScore / Ranks: 2478
7.60
JIF / Ranks: 1162
5.9
Recent Articles
1.
Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):27.
PMID: 40069204
Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat...
2.
Rajagopal P, Reid S, Fan R, Venton L, Weidner A, Roberson M, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):28.
PMID: 40069179
We determined triple-negative breast cancer (TNBC) subtypes, genetic ancestry, and immune features in a cohort of self-reported Black females with TNBC diagnosed at or below age 50. Among 104 tumors,...
3.
Jensen M, Nielsen T, Bartlett J, Laenkholm A, Shepherd L, Ejlertsen B
NPJ Breast Cancer
. 2025 Mar;
11(1):26.
PMID: 40064871
NCIC-CTG MA.5 and DBCG 89D are symmetrically designed randomized trials comparing adjuvant cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in high-risk breast cancer patients. In a joint analysis...
4.
Scandino R, Nardone A, Casiraghi N, Galardi F, Genovese M, Romagnoli D, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):25.
PMID: 40057527
Cell-free DNA (cfDNA) extracted from peripheral blood has emerged as a crucial biomarker source in oncology research. To enhance the detection of somatic copy number alterations (SCNAs) and circulating tumor...
5.
Felsheim B, Fernandez-Martinez A, Fan C, Pfefferle A, Hayward M, Hoadley K, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):24.
PMID: 40057511
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that remains challenging to target with traditional therapies and to predict risk. We provide a comprehensive characterization of 238 stage...
6.
Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):23.
PMID: 40055382
Breast cancer (BC) represents a heterogeneous ecosystem and elucidation of tumor microenvironment components remains essential. Our study aimed to depict the composition and prognostic correlates of immune infiltrate in early...
7.
Grinda T, Morganti S, Hsu L, Yoo T, Kusmick R, Aizer A, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):22.
PMID: 40038301
Central nervous system (CNS) metastases are associated with poor prognosis in patients with metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) in...
8.
Tamirisa N, Dong W, Shen Y, Lin H, Shaitelman S, Babiera G, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):21.
PMID: 39987164
We sought to determine whether sequencing of treatment impacted outcomes in older, comorbid patients. Using the National Cancer Database(2010-2017), 2911 patients >70 with a Charleson Deyo Comorbidity(CCDM) score of 2/3...
9.
Turova P, Kushnarev V, Baranov O, Butusova A, Menshikova S, Yong S, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):19.
PMID: 39979291
Current breast cancer classification methods, particularly immunohistochemistry and PAM50, face challenges in accurately characterizing the HER2-low subtype, a therapeutically relevant entity with distinct biological features. This notable gap can lead...
10.
Bottosso M, Griguolo G, Guiu S, Guarascio M, Bailleux C, Miglietta F, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):20.
PMID: 39979277
Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with...